Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$486K Sell
1,341
-35
-3% -$12K 0.17% 99
2026
Q1
$484K Buy
1,376
+35
+3% +$12.5K 0.2% 97
2025
Q4
$439K Buy
1,341
+32
+2% +$10.2K 0.19% 100
2025
Q3
$369K Sell
1,309
-9
-0.7% -$2.61K 0.17% 111
2025
Q2
$368K Buy
1,318
+5
+0.4% +$1.42K 0.18% 110
2025
Q1
$409K Buy
1,313
+4
+0.3% +$1.18K 0.23% 99
2024
Q4
$341K Buy
+1,309
New +$388K 0.18% 116

Other funds holding AMGN

YANKCOM Partnership's AMGN Position: Q2 2026 in Review

YANKCOM Partnership reduced its Amgen (AMGN) stake by 2.5% in Q2 2026, selling an estimated $12K and leaving 1,341 shares worth $486K. The position accounts for 0.17% of the portfolio, ranked #99.

YANKCOM Partnership first reported a position in AMGN in Q4 2024 and has held it in 7 quarters since. 1,998 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • YANKCOM Partnership held 1,341 shares of Amgen worth $486K as of Q2 2026.
  • YANKCOM Partnership sold 35 Amgen shares in Q2 2026, an estimated $12K.
  • Amgen made up 0.17% of YANKCOM Partnership's portfolio in Q2 2026, its #99 holding.
  • YANKCOM Partnership first reported a position in Amgen in Q4 2024 and has held it in 7 quarters since.
  • 1,998 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on YANKCOM Partnership's 13F filing for Q2 2026, filed 21 Jul 2026.